June 2nd 2024
CHAARTED2 trial showed an improved progression-free survival in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel, abiraterone acetate, and prednisone.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
PARP Inhibition in Prostate Cancer: A Promising Approach
May 15th 2016Having said that, PARP inhibition is one of the most promising approaches for “precision therapy” so far. Within the next few years and with the help of ongoing clinical trials, we should have a better understanding of whether or not the high expectations raised will be translated into clinical reality.
Bicalutamide/Everolimus Combo Promising in CRPC
April 14th 2016Combination therapy with bicalutamide and everolimus resulted in promising responses in a phase II trial of patients with castration-resistant prostate cancer, though a substantial proportion of patients experienced everolimus-related toxicities.
Adding Bevacizumab to ADT Improved Relapse-Free Survival in Early-Stage Prostate Cancer
April 8th 2016Results of a phase II randomized trial found that combining a short course of androgen deprivation therapy with bevacizumab improved relapse-free survival in men with hormone-sensitive prostate cancer.
Toxicities May Affect Readiness of Hypofractionation in Prostate Cancer
March 26th 2016The phase III HYPRO study failed to prove the non-inferiority of using hypofractionated radiotherapy compared with fractionated radiotherapy for late genitourinary and gastrointestinal toxicity in men with intermediate- or high-risk prostate cancer.
The Quest for an Evidence-Based Approach to Intermediate-Risk Prostate Cancer
March 15th 2016We must now come to a uniform consensus regarding the descriptions of these risk groups in order to truly determine which treatments have the best oncologic efficacy, while minimizing overtreatment and optimizing patients’ quality of life.